The biotechnology firm said the results of work undertaken by Queen Mary University of London's Barts Cancer Institute showed that Parsortix had delivered a “dramatically higher performance” in testing for prostate cancer which then yielded a positive tissue sample, or biopsy.
READ: ANGLE’s Parsortix system could help “significantly improve” diagnosis and treatment of lung cancer
The current standard involves a blood test that ANGLE said had high false-positive rates, resulting in unnecessary tissue biopsies which did not contain cancer cells.
However, using Parsortix 93% of 41 positive results did result in cancer cell detection, meaning that if combined with the existing blood test could prevent a “substantial proportion” of unnecessary biopsies without missing clinically significant prostate cancer cases.
The data from the study will be published in the peer-reviewed Journal of Urology.
"This is a major new study from Barts Cancer Institute demonstrating potential for ANGLE's Parsortix system to transform care in early stage diagnosis for the most prevalent cancer type in men”, said ANGLE’s chief executive, Andrew Newland.
“Prostate cancer is a high priority for the company's development once we have concluded our current FDA and verification studies in breast cancer and ovarian cancer.”